Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19)
Julie Boucau, Rockib Uddin, Caitlin Marino, James Regan, James P. Flynn, Manish C. Choudhary, Geoffrey Chen, Ashley Stuckwisch, Josh Mathews, May Y. Liew, Arshdeep Singh, Zahra Reynolds, Surabhi Iyer, Grace Chamberlin, Tammy D. Vyas, Jatin M. Vyas, Sarah E. Turbett, Jonathan Z. Li, Jacob E. Lemieux, Amy K. Barczak, Mark J. Siedner
Abstract
We enrolled 7 individuals with recurrent symptoms or antigen test conversion following nirmatrelvir-ritonavir treatment. High viral loads (median 6.1 log10 copies/mL) were detected after rebound for a median of 17 days after initial diagnosis. Three had culturable virus for up to 16 days after initial diagnosis. No known resistance-associated mutations were identified.
Topics & Concepts
MedicineRitonavirCoronavirus disease 2019 (COVID-19)VirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakCoronavirusViral loadViral diseaseVirusInternal medicineImmunologyDiseaseInfectious disease (medical specialty)Antiretroviral therapyOutbreakSARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testingAnimal Virus Infections Studies